New epitopes in ovalbumin provide insights for cancer neoepitopes

Area of Science:

• Immunology
• Oncology
• Bioinformatics

Background:

• MHC class I-restricted epitopes of chicken ovalbumin (OVA) were initially identified using CD8 T cells.
• Understanding T cell epitope presentation is crucial for cancer immunotherapy.

Purpose of the Study:

• To identify novel OVA epitopes using bioinformatics.
• To investigate CD8 T cell responses to known and novel OVA epitopes in a tumor model.
• To assess the therapeutic potential of these epitopes in established tumors.

Main Methods:

• Bioinformatic analysis to identify OVA epitopes.
• In vivo assessment of CD8 T cell responses in OVA-transgenic and E.G7 tumor-bearing C57BL/6 mice.
• Treatment of tumor-bearing mice with anti-CTLA4 antibody.

Main Results:

• Four new OVA epitopes and one cryptic epitope were identified.
• No CD8 T cell responses were detected in mice with growing E.G7 tumors or those immunized with the tumor.
• CD8 T cell responses to SIINFEKL and EKYNLTSVL were observed only after anti-CTLA4 treatment.
• All identified epitopes failed to treat established tumors.

Conclusions:

• The therapeutic efficacy of neoepitopes identified by CD8 responses in tumor-bearing hosts needs critical reassessment.
• Tumor microenvironment, particularly regulatory T cells, significantly impacts T cell responses to epitopes.
• Novel epitope identification alone does not guarantee therapeutic success in cancer treatment.